Vipul M. Joshi, MD
Specialist
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,030
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
FL license ME87414
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Josephs Hospital Tampa, FL
Medical groups
- Vipul Joshi, MD PA (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,030
- Services billed
- 659,242
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 340,000 | 99 |
| Injection, romosozumab-aqqg, 1 mg | 101,220 | 92 |
| Injection, tocilizumab, 1 mg | 64,043 | 24 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 40,500 | 66 |
| Injection, denosumab, 1 mg | 32,700 | 343 |
| Injection, golimumab, 1 mg, for intravenous use | 28,850 | 37 |
| Injection, rituximab, 10 mg | 3,900 | 14 |
| Injection, infliximab, excludes biosimilar, 10 mg | 3,751 | 13 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 2,727 | 466 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 2,541 | 319 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tramadol Hcl Other prescribers in Brandon, FL | 284 |
| Pregabalin Other prescribers in Brandon, FL | 122 |
| Hydroxychloroquine Sulfate Other prescribers in Brandon, FL | 23 |
| Enbrel Sureclick (etanercept) Other prescribers in Brandon, FL | 17 |
| Humira Pen (adalimumab) Other prescribers in Brandon, FL | 15 |
| Duloxetine Hcl Other prescribers in Brandon, FL | 13 |
| Methotrexate (methotrexate sodium) Other prescribers in Brandon, FL | 13 |
| Clonazepam Other prescribers in Brandon, FL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 173 payments worth $4,573 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,430 |
|---|---|
| Amgen Inc. | $910 |
| AbbVie Inc. | $381 |
| UCB, Inc. | $355 |
| Ani Pharmaceuticals, Inc. | $292 |
| AstraZeneca Pharmaceuticals LP | $279 |
| Novartis Pharmaceuticals Corporation | $240 |
| GlaxoSmithKline, LLC. | $165 |
| Food and Beverage | $3,383 |
|---|---|
| Travel and Lodging | $1,164 |
| Education | $25.70 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 5, 2025 | Travel and Lodging IMMUNOLOGY · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $807 |
| Merck Sharp & Dohme LLC Sep 5, 2025 | Travel and Lodging IMMUNOLOGY · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $178 |
| Merck Sharp & Dohme LLC Sep 6, 2025 | Travel and Lodging IMMUNOLOGY · travel to Chicago, IL · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $178 |
| Merck Sharp & Dohme LLC Oct 2, 2025 | Education IMMUNOLOGY · in-kind | $25.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 15 industry-funded studies in 2025, from 7 companies. The companies reported $159,060 in research payments for these studies, mostly to the institutions running them.
- A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus
Janssen Research & Development, LLC - A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
AstraZeneca UK Limited - A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthriti…
Janssen Research & Development, LLC - A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
UCB SA · Completed · NCT04009499 - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Recruiting · NCT06617325 - A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome
Novartis Pharmaceuticals Corporation - A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
UCB SA · Enrolling by invitation · NCT04976322 - A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
UCB SA · Completed · NCT04294667 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - A 5-year prospective observational registry to assess adverse events o
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.